ATXS
Price
$5.81
Change
+$0.08 (+1.40%)
Updated
Jul 3 closing price
Capitalization
327.88M
37 days until earnings call
URGN
Price
$13.58
Change
+$0.62 (+4.78%)
Updated
Jul 3 closing price
Capitalization
626.14M
45 days until earnings call
Interact to see
Advertisement

ATXS vs URGN

Header iconATXS vs URGN Comparison
Open Charts ATXS vs URGNBanner chart's image
Astria Therapeutics
Price$5.81
Change+$0.08 (+1.40%)
Volume$188.85K
Capitalization327.88M
UroGen Pharma
Price$13.58
Change+$0.62 (+4.78%)
Volume$737.41K
Capitalization626.14M
ATXS vs URGN Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. URGN commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ATXS: $5.81 vs. URGN: $13.58)
Brand notoriety: ATXS and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 39% vs. URGN: 20%
Market capitalization -- ATXS: $327.88M vs. URGN: $626.14M
ATXS [@Biotechnology] is valued at $327.88M. URGN’s [@Biotechnology] market capitalization is $626.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, URGN is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 6 TA indicator(s) are bullish while URGN’s TA Score has 6 bullish TA indicator(s).

  • ATXS’s TA Score: 6 bullish, 4 bearish.
  • URGN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ATXS and URGN are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а +6.80% price change this week, while URGN (@Biotechnology) price change was +3.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

URGN is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($626M) has a higher market cap than ATXS($328M). URGN YTD gains are higher at: 27.512 vs. ATXS (-35.011). URGN (-119.79M) and ATXS (-124.4M) have comparable annual earnings (EBITDA) . ATXS has more cash in the bank: 295M vs. URGN (196M). ATXS has less debt than URGN: ATXS (5.06M) vs URGN (125M). URGN has higher revenues than ATXS: URGN (91.9M) vs ATXS (0).
ATXSURGNATXS / URGN
Capitalization328M626M52%
EBITDA-124.4M-119.79M104%
Gain YTD-35.01127.512-127%
P/E RatioN/AN/A-
Revenue091.9M-
Total Cash295M196M151%
Total Debt5.06M125M4%
FUNDAMENTALS RATINGS
ATXS vs URGN: Fundamental Ratings
ATXS
URGN
OUTLOOK RATING
1..100
8491
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (59) in the Biotechnology industry is in the same range as URGN (73). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as URGN (100). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as URGN (100). This means that ATXS’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (35) in the Biotechnology industry is in the same range as ATXS (55). This means that URGN’s stock grew similarly to ATXS’s over the last 12 months.

URGN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that URGN’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSURGN
RSI
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RCGTX15.000.21
+1.42%
Virtus Zevenbergen Technology C
UBPSX15.890.18
+1.15%
ProFunds UltraLatin America Svc
NCGFX67.480.56
+0.84%
New Covenant Growth
RYSYX78.970.65
+0.83%
Rydex S&P 500 C
ITHSX54.970.42
+0.77%
Hartford Capital Appreciation R4

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.40%
DNLI - ATXS
57%
Loosely correlated
-1.41%
XENE - ATXS
54%
Loosely correlated
-0.33%
CRNX - ATXS
54%
Loosely correlated
+1.22%
TRDA - ATXS
53%
Loosely correlated
-0.55%
APGE - ATXS
52%
Loosely correlated
+7.08%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+4.78%
AIM - URGN
39%
Loosely correlated
-3.47%
ETNB - URGN
38%
Loosely correlated
+0.59%
ATXS - URGN
36%
Loosely correlated
+1.40%
SCPH - URGN
36%
Loosely correlated
-1.73%
PHAT - URGN
35%
Loosely correlated
+0.11%
More